Abstract: A method for treating and controlling the symptoms of neuropsychopharmacological disorders and neurodegenerative diseases associated with or resulting from excessive activation of the N-methyl-D-aspartate receptor complex which comprises administering to warm-blooded animals in need of such treatment, 2-phenyl-1,3-propanediol dicarbamate, the neuroprotective effects of which are at least partially mediated through a strychnine-insensitive glycine receptor mechanism is disclosed.

Abstract: Methods and compositions for treating acute or chronic pain in a mammal comprising administering a therapeutically effective amount of an analgesic solution comprising at least one branched chain amino acid selected from the group consisting of leucine, isoleucine, and valine, or administering a therapeutically effective amount of an analgesic solution comprising an analgesic agent selected from the group consisting of an opioid, an agonistic-antagonistic agent, and an anti-inflammatory agent, and at least one branched chain amino acid selected from the group consisting of leucine, isoleucine, and valine. A method and composition for treating addiction to narcotic drugs comprises administering a therapeutically effective amount of a solution comprising methadone and at least one branched chain amino acid selected from the group consisting of leucine, isoleucine, and valine.

Abstract: A preparation for the treatment and prevention of thromboses and thromboembolic complications is disclosed, which preparation has a content of protein S at a concentration at least 50 times that present in native plasma and is free from C4b-binding protein, optionally in combination with a content of activated protein C.

Abstract: The present invention relates to a pharmaceutical composition comprising: (a) a compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 are as defined below; and (b) isosorbide 5-mononitrate or isosorbide 2-mononitrate or glycerol trinitrate or glycerol 1-mononitrate or glycerol 2-mononitrate: and, optionally (c) a pharmaceutically acceptable carrier. The composition is useful in the prevention and treatment of cardiovascular diseases, and is especially useful in the prevention and treatment of angina pectoris and myocardial infarction.

Abstract: A pharmaceutical composition useful for treating gastroesophageal reflux comprising oxethazaine and a carrier selected from alginic acid and alginates.

Abstract: The hardening agent contains a composition comprised of tannic acid and potassium aluminum sulfate in a ratio of tannic acid to potassium aluminum sulfate ranging from 10 to 1 to 1 to 50 and a stabilizing agent extracted from crude drugs of plants containing a phenol, flavon, flavonoid, catechin or a polycarboxylic acid.

Abstract: There are disclosed pharmaceutical preparations and methods for the use thereof which have a cardioprotective action useful in coronary insufficiency, in the prevention of the constitution of an infarction or of sudden death. It consists in the utilization of amiodarone, a nitrate derivative and a beta-blocker.

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a phenylpyrrolidine compound.

Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of depression.

Abstract: A compound of the formula ##STR1## wherein A together with the two carbon atoms denoted by .alpha. and .beta. is the group ##STR2## and further wherein the substituents R.sup.1, R.sup.2, and R.sup.3 are as described in the specification, can be used in the treatment of neurological symptoms which are associated with circulatory disorders of the brain, especially in the treatment of neurological symptoms which are associated with cerebrovascular seizures.

Abstract: A pharmaceutical composition (orally or parenterally administered) containing glycyl-p-amino-pyridine monoacetate alone or together suitable carriers, which shows surprising anti-amnesic and anti-Alzheimer properties, is described.

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a nicotine compound. Exemplary nicotine compounds are 5-fluoronicotine, 5-bromonicotine, 4.sup.1 -methylnicotine and 5-methylnicotine.

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a cytisine compound.

Abstract: A method useful for the treatment or prevention of diseases caused by a massive release of cerebral glutamate, in particular epilepsy and dementia, and pharmaceutical formulations therefor, which comprise, as an active ingredient, a therapeutically effective amount of methyl (+)-(4S)-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3-b]pyr idine-5-carboxylate (S-312-d).

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a gamma-nicotine compound.

Abstract: A method for treating circadian rhythm disorders is described. The method involves the administration of melatonin from about 6 hours to about 19 hours prior to when the normal sleep phase should begin, depending on whether a phase advance shift in circadian rhythms or a phase delay shift is desired. This is typically from about 4 hours to about 17 hours prior to the time of endogenous melatonin onset.

Abstract: A composition which is percutaneously absorbable, including a narcotic analgesic selected from the group consisting of morphine and analogous analgesics thereof; from 1 to 20 weight percent of a percutaneous absorption accelerator comprised of one of (a) a terpene and (b) an essential oil; from 10 to 60 weight percent of a percutaneous absorption accelerating assistant comprised of one of (a) a lower alcohol having 1-5 carbon atoms, (b) water and (c) a lower glycol having 2-5 carbon atoms.

Abstract: Methods of treating reduced insulin-like growth factor levels and bone loss associated with aging which include administering L-carnitine and/or its precursors thereof are disclosed. Such administration results in increased serum insulin-like growth factor-1 and osteocalcin levels.

Abstract: A method is disclosed for inducing thromboxane suppression in a mammalian subject by percutaneously administering a pharmaceutical composition containing aspirin. Articles useful for practicing the therapeutic methods of the invention are also disclosed.

Abstract: A pharmaceutical composition which comprises a mixture of an alpha-2 adrenoceptor antagonist, preferably idazoxan, or a pharmaceutically acceptable salt thereof, and either a catecholamine precursor or an inhibitor of aromatic L-amino acid decarboxylase, preferably carbidopa. The compositions can be used for treatment of endogenous depression or low blood pressure.